Latest Articles and Analysis

Rising employer premiums averaging 9.5% erode wages, forcing workers to delay care.

Break Up Big Medicine Act would force structural separation of insurers, PBMs, and pharmacies.

Medicare drug negotiation's third wave includes Biktarvy, raising HIV treatment access concerns.

Enhanced ACA subsidies expired Jan 1; Senate framework proposes two-year extension with restrictions.

European price controls demonstrate MFN policy risks: delayed access, treatment rationing, and pharmaceutical innovation collapse.

September government shutdown threatens healthcare systems during November open enrollment, risking coverage loss for 22 million Americans.

Most Favored Nation pricing threatens to import restrictive QALY-based frameworks that discriminate against expensive treatments.

Expiration of enhanced ACA subsidies threatens to increase premiums 75% and reduce marketplace enrollment by millions.

Pharmacy benefit managers extract billions while adding no value, increasing costs without improving patient access or health outcomes.

Trump administration's contradictory drug pricing policies undermine goals of affordability and innovation incentives.

Copay accumulator programs exclude patient assistance from deductibles, creating barriers to medication adherence and treatment.

FTC investigation confirms pharmacy benefit managers extracted billions in excess revenue through specialty drug markup schemes.

Insurance companies deploy AI algorithms for automated prior authorization denials, restricting patient access to prescribed treatments.

Federal policy failures on copay accumulator programs restrict patient assistance benefits.

FTC complaint against major PBMs for anticompetitive rebating and insulin pricing.

Unintended consequences of Inflation Reduction Act drug pricing provisions.

Copay accumulator schemes and Essential Health Benefits loophole; Louisiana as model.

How payor cost-containment strategies drive health disparities and limit care access.

PBM practices and supply chain vulnerabilities enable counterfeit drug distribution.

Rising medical debt burden among insured Americans and systemic causes.